Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 235

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 235
---
 |     |        | 484,512 |     |        |           |     |        |         |     |       |   |     |              |        |     |              | 1,175,239 |     |           | 1,659,751 |
| Former Executive Chairman                                                        |     |      | 2023 |     |        | 638,040 |     |        | 1,451,968 |     |        |       — |     |       | — |     |              | 72,306 |     |              |         — |     |           | 2,162,314 |
| Loretta Itri (9)                                                                 |     |      | 2024 |     |        | 403,936 |     |        |   194,543 |     |        |  57,600 |     |       |   |     |              |        |     |              |   973,995 |     |           | 1,630,074 |
| Former Chief Medical Officer                                                     |     |      | 2023 |     |        | 521,475 |     |        |   858,234 |     |        |       — |     |       | — |     |              | 44,322 |     |              |    51,654 |     |           | 1,475,685 |

| (1) | The amounts reported in the Option Awards column represent the grant date fair value of the stock options                                                                                                                                                
 granted to the named executive officers as of the grant date as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, not including any estimates of forfeitures. Note that the amounts reported 
 in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the named executive officers from the options.                                                            |

The Company uses the Black-Scholes option pricing model to determine the estimated fair value for share-based option awards. Option pricing and models require the input of various assumptions, including the option’s expected life, expected dividend yield, price volatility and risk-free interest rate of the underlying stock. Forfeitures are recognized and accounted for as they occur. The calculation was based on the following assumptions:

|                                                    |     |     Year Ended 
   December 31, 
           2024 |
|:---------------------------------------------------|:----|---------------:|
| Weighted average grant date fair value (per share)